The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alongside Deputy Prime Minister Heng Swee Keat, DPM Gan would provide a steady hand during the initial transition and help mentor the younger office-holders, said the then incoming prime minister.

The detention of several AstraZeneca employees and eventually the company’s China president Leon Wang unsettled investors, fueling fears of a crackdown similar to the GSK scandal 10 years ago.

For example, more than half of the biopharma executives Deloitte surveyed said their companies need to rethink their R&D and product development strategies over the next 12 months. Companies may ...

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to ...

A look at the shareholders of Sutro Biopharma, Inc. (NASDAQ:STRO) can tell us which group is most powerful. With 69% stake, institutions possess the maximum shares in the company. In other words ...

In a separate transaction, Akamis Bio signed a licensing agreement that grants Xuanzhu Biopharma rights to NG-350A in the Greater China region. The terms state that Akamis Bio is eligible to ...

As touched upon, a few decades ago, Japan was a global powerhouse when it came to biopharma innovation, as companies in the country invested heavily in research and development (R&D), aided at the ...

Statements included in this release that are not a description of historical facts are forward-looking statements. Words or phrases such as “believe,” “may,” “could,” “will ...